Back to Search
Start Over
Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis.
- Source :
- British Journal of Haematology; May2024, Vol. 204 Issue 5, p1811-1815, 5p
- Publication Year :
- 2024
-
Abstract
- Summary: Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple‐class refractory disease. We report the use of belantamab mafodotin, a BCMA‐directed drug–antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty‐one patients were reviewed, with a median of three prior lines of therapy. The median follow‐up was 12 months (95% CI 4–19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty‐eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis. [ABSTRACT FROM AUTHOR]
- Subjects :
- PLASMA cell diseases
AMYLOIDOSIS
ANTIBODY-drug conjugates
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 204
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 177190909
- Full Text :
- https://doi.org/10.1111/bjh.19286